SUMMARY Increasing amounts of porcine secretin (0.05 to 2.00 clinical unitsfhl100 g body wt) given to rats during a continuous infusion of bilirubin, increased bile flow and the apparent maximal biliary excretion of bilirubin ('Tm'). This increment was caused by an enhanced biliary output of bilirubin monoconjugates. The effect was dose dependent but maximal at a secretin infusion of 0-80 CU. Somatostatin 0.2 and 0.8 ptg/h/100 g body wt caused a dose related inhibition of the hepatic effects of secretin both on bile flow and on biliary output of bilirubin conjugates. As secretin elicits the release of somatostatin, a feed-back system could be envisaged whereby the somatostatin released stops the effects of secretin.
0-80 CU. Somatostatin 0.2 and 0.8 ptg/h/100 g body wt caused a dose related inhibition of the hepatic effects of secretin both on bile flow and on biliary output of bilirubin conjugates. As secretin elicits the release of somatostatin, a feed-back system could be envisaged whereby the somatostatin released stops the effects of secretin.
An increasing number of gastrointestinal polypeptide hormones are being documented. A vast amount of information concerning their functions and mode of action on stomach, gut and pancreas is available' but only a limited number of studies have dealt with hepatic effects, '-" although the liver is the first organ placed on the venous effluent of the GI hormone secreting organs.
In the rat, secretin produces a mild but short lasting choleresis. Because secretin as well as other gastrointestinal hormones elicit the release of somatostatin' and as the latter was shown to be cholestatic in rath and dog,"'" our aim was to test the hypothesis that somatostatin could block or interfere with the hepatic effects of secretin. A type of feed back system could be envisaged whereby the secretin released as a response to feeding, stimulates the secretion of somatostatin which in its turn would end the effects of secretin.
Methods

ANIMALS
Male Wistar R-rats weighting 280-340 g were used. Approximately 20 min after anaesthesia with sodium pentobarbital (6 mg/100 g body wt, ip) the bile duct and the right jugular vein were cannulated (catheters with internal to external diameters of 0-3-0-7 mm and 05-4)09 mm respectively, Biotrol Pharma, Paris, France) while the animals were kept on heating plates. Rats were then put in restraining cages and placed in thermostatically controlled boxes for three hours to allow recovery from anaesthesia and to maintain body temperature at 37 1 (0.3) 'C; during this period they received 5% glucose in 0( 16 M NaCI iv at the rate of 1 2 ml/h/100 g body wt. The jugular catheter was connected by a three way tap to two different perfusors (Braun, Melsungen, Germany) to allow later injection of different solutions. Bile was collected in the dark in preweighed plastic tubes over 10 min periods.
Unconjugated bilirubin-IX(x (containing less than 5% of non-a isomers) (Sigma, St Louis, MD) was solubilised in 150 mM NaOH. The final pH of the bilirubin solution was brought to pH 9*5 just before the injection. Three hours after surgical preparation, rats were given a constant infusion of bilirubin at a rate of 256 nmol/min/100 g body wt after a priming dose a 3 42 smol/10() g body wt to obtain a maximal secretory rate of bile pigments ('Tm').' The . 4 -, Results are given as mean ± 1 standard deviation. Statistical significance was evaluated by a Wilcoxon's rank-sum test for paired data, to compare the basal (Tm) and experimental (somatostatin) period within each animal.
RK.SUl lS
Secretin produced a dose related increase of bile flow (Table) . The stimulating effect of secretin was maximal at the rate of 0(8 cu/h/l00 g body wt.
Because the pigment concentration in bile was com- parable in all animals studied (mean value ± 1 SD; 27-5 mM (2. 1)), the biliary bilirubin output varied in parallel with the bile flow. The enhancement in bilirubin Tm was due to an increased secretion rate of monoconjugates; their fractional amount rose from 52% (2) in controls to 57% (2) at 0(8 cu of secretin.
Somatostatin interfered in a dose dependent fashion with the stimulatory effects of secretin (Table) . The Impurities in the administered secretin preparation or prolonged collection periods'" '' or the use of rats still under anaesthesia'7 or below physiological body temperature have led to controversies whether secretin is choleretic or not in the rat. ""' Anaesthesia or low body temperature induce cholestasis7'' but our rats, having recovered at least for three hours from the anaesthesia and having a normal body temperature, showed a short lasting choleresis under purified porcine GIH secretin; it was dose related and the maximal increment of bile flow amounted up to 15-20% (Table) . This choleresis was paralleled by an enhanced maximal output of bilirubin monoconjugates without any alteration of the diconjugate excretion, in contrast with what is seen after a 90-120 min pretreatment with secretin.7 The fact that the choleretic effect of secretin tended to fade out despite continuation of the polypeptide7 has led us to examine the hypothesis that secretin might stimulate release of an inhibitory peptide such as somatostatin. The latter indeed decreases bile flow6 II 1" but in itself had no effect on bilirubin-Tm. 22 The present studies demonstrate that somatostatin hampers in a dose dependent fashion the effects exerted by secretin on bile flow and maximal bilirubin output. These data are compatible with our hypothesis that secretin, released in response to feeding, produces an enhanced bile flow but at the same time triggers somatostatin release. The latter then counteracts the choleretic effect of secretin. As a result only a shortlasting choleresis is observed after secretin. This hypothesis and its pathophysiological relevance will have to be confirmed by direct measurements of concentrations of somatostatin in the portal vein during secretin infusion or during feeding. From a comparison made with data obtained by others, however, it seems that the presently infused amounts are not out of proportion. In the rat' and dog"4 somatostatin concentrations in peripheral blood approximate 0-234)-30 ng/ml whereas portal vein With regard to the secretin infusion, an amount of 0-03 CU/h/100 g body wt given in man leads to plasma levels as obtained during acidification of the duodenum"' whereas 0)27 CU seems to lead to a maximal stimulation of pancreatic bicarbonate." For comparison, our rats received amounts of secretin between 0(10 and 2-0() CU with a maximal effect on bile flow at a rate of 0(80 CU. Thus, the dosages presently used appear only slightly supraphysiological.
At this moment it is clear that somatostatin interacts with the hepatic effects of secretin on bile flow and maximal hepatic bilirubin transport. Whether somatostatin would also inhibit the release of secretin in response to feeding, besides having an end organ inhibitory effect, cannot be deduced from the present experiments. 
